News | June 03, 2022
Lockwood acquires medical animation studio ‘Random42’ from Graphite Capital
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Follows Zealand Pharma’s appointment of Adam Steensberg as CEO and decision to refocus strategy
Facility features LED lighting, solar panels, automation and innovative temperature-controlled systems to maximize efficiency and minimize environmental impact
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
GSK to pay $2.1 billion upfront and up to $1.2 billion in potential development milestones
The proposed demerger is the most significant corporate change for GSK in the last 20 years
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
120+ members of multi-disciplinary medical team are trained to provide seamless, outcome driven trauma and emergency care
Subscribe To Our Newsletter & Stay Updated
